Showing 1061-1070 of 1211 results for "".
- Bausch + Lomb Will Present New Scientific Data and Analyses on Products and Pipeline Programs During ARVOhttps://modernod.com/news/bausch-lomb-will-present-new-scientific-data-and-analyses-on-products-and-pipeline-programs-during-arvo/2480814/Bausch + Lomb announced the presentation of 13 scientific poster presentations during the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, which will take place in Denver, Colorado, from May 1-4, 2022, and virtually from May 11-12, 2022. The presentations incl
- Recent Alimera Data Featured in Scientific Programming at ARVOhttps://modernod.com/news/recent-alimera-data-featured-in-scientific-programming-at-arvo/2480813/Alimera Sciences announced today that Iluvien will be highlighted in various scientific abstracts at the annual Association for Research in Vision and Ophthalmology (ARVO) conference being held in Denver, Colorado from May 1-4 and virtually May 11-12, 2022.
- Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the 2022 ARVO Annual Meetinghttps://modernod.com/news/graybug-to-present-preclinical-data-for-gb-401-in-primary-open-angle-glaucoma-at-the-2022-arvo-annual-meeting/2480808/Graybug Vision announced a poster presentation of preclinical data for GB-401 in primary open-angle glaucoma (POAG) at the upcoming Association for Research in Vision and Ophthalmology (ARVO) annual meeting, to be held at the Colorado Convention Center in Denver from May 1-4, 20
- Oyster Point Pharma to Present New Analyses at ARVO 2022https://modernod.com/news/oyster-point-pharma-to-present-new-analyses-at-arvo-2022/2480807/Oyster Point Pharma announced the presentation of data analyses at the Association for Research in Vision and Ophthalmology (ARVO) 2022, being held on May 1-4. “We are pleased to be presenting new analyses of the pivotal trial data of Tyrvaya&n
- Allegro Ophthalmics Announces New Scientific Data to Be Presented During the 2022 ARVO Annual Meetinghttps://modernod.com/news/allegro-ophthalmics-announces-new-scientific-data-to-be-presented-during-the-2022-arvo-annual-meeting/2480806/Allegro Ophthalmics announced that two scientific posters involving risuteganib, the company’s lead investigational compound in retina, will be presented during the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. ARVO 2022 will be held May 1-4, 2022 in
- Visus Therapeutics Announces New Scientific Data to Be Presented During the 2022 ARVO Annual Meetinghttps://modernod.com/news/visus-therapeutics-announces-new-scientific-data-to-be-presented-during-the-2022-arvo-annual-meeting/2480805/Visus Therapeutics announced that it will present new scientific data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held May 1-4, 2022 in Denver, Colorado. The two presentations will highlight topics on new research findings on Brimochol PF, th
- Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational NOV03 at ASCRShttps://modernod.com/news/bausch-lomb-presents-data-from-first-pivotal-phase-3-trial-of-investigational-nov03-at-ascrs/2480800/Bausch + Lomb and Novaliq announced that data from the first pivotal phase 3 trial (GOBI) of NOV03 (perfluorohexyloctane), which is being investigated as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibom
- Bausch + Lomb and Clearside Biomedical Announce US Commercial Launch of Xiperehttps://modernod.com/news/bausch-lomb-and-clearside-biomedical-announce-us-commercial-launch-of-xipere/2480725/Bausch + Lomb announced the US commercial launch of Xipere (triamcinolone acetonide injectable suspension), the first and only therapy approved by the FDA for suprachoroidal use for the treatment of macular edema associated with uveitis. "Xipere is the first and
- RG6501 (OpRegen) Full Phase 1/2a Results to Be Presented at ARVO Annual Meetinghttps://modernod.com/news/rg6501-opregen-full-phase-12a-results-to-be-presented-at-arvo-annual-meeting/2480697/Lineage Cell Therapeutics announced that full results from a phase 1/2a clinical study of RG6501 (OpRegen), a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD), will be presented at the 2022 Associ
- Eyenuk Announces Publication of Strong EyeArt Pivotal Clinical Trial Results in JAMA Network Openhttps://modernod.com/news/eyenuk-announces-publication-of-strong-eyeart-pivotal-clinical-trial-results-in-jama-network-open/2480451/Eyenuk announced that strong results from the EyeArt prospective, multicenter pivotal clinical trial were published as an original investigation in JAMA Network Open, a peer-reviewed medical journal published by the American Medical Association. The artic